BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/23/2024 4:13:00 AM | Browse: 463 | Download: 1309
Publication Name World Journal of Clinical Oncology
Manuscript ID 89466
Country Italy
Received
2023-11-01 20:40
Peer-Review Started
2023-11-01 20:43
First Decision by Editorial Office Director
2023-11-29 01:42
Return for Revision
2023-11-29 01:42
Revised
2023-12-07 10:25
Publication Fee Transferred
Editorial Processing by Scientific Editor
2023-12-24 23:31
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2024-01-02 06:51
Articles in Press
2024-01-02 06:51
Edit the Manuscript by Language Editor
Typeset the Manuscript
2024-01-13 12:56
Publish the Manuscript Online
2024-01-23 04:13
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Uveal melanoma: Recent advances in immunotherapy
Manuscript Source Invited Manuscript
All Author List Francesco Saverio Sorrentino, Francesco De Rosa, Patrick Di Terlizzi, Giacomo Toneatto, Andrea Gabai, Lucia Finocchio, Carlo Salati, Leopoldo Spadea and Marco Zeppieri
ORCID
Author(s) ORCID Number
Francesco De Rosa http://orcid.org/0000-0003-0511-1298
Carlo Salati http://orcid.org/0000-0003-4736-5296
Leopoldo Spadea http://orcid.org/0000-0002-1190-3956
Marco Zeppieri http://orcid.org/0000-0003-0999-5545
Funding Agency and Grant Number
Corresponding Author Marco Zeppieri, BSc, MD, PhD, Doctor, Doctor, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy. markzeppieri@hotmail.com
Key Words Uveal melanoma; Immunotherapy; Ocular oncology; Tumor; Metastatic disease; Genetic mutations
Core Tip Our minireview will cover the latest studies about immunotherapy for uveal melanoma (UM) metastatic disease. Driver genes and oncogenic mutations have been largely investigated. Up to half of affected patients develop metastases that are the leading single cause of death after diagnosis of UM. Precise systemic therapy addressing metastatic UM and significantly improving the surveillance is not available for each single case. However, identifying predictive factors, achieving international consensus on surveillance protocols, aiming to inactivate micrometastases, and standardizing outcomes would be crucial to be able to effectively cure metastatic UM.
Publish Date 2024-01-23 04:13
Citation Sorrentino FS, De Rosa F, Di Terlizzi P, Toneatto G, Gabai A, Finocchio L, Salati C, Spadea L, Zeppieri M. Uveal melanoma: Recent advances in immunotherapy. World J Clin Oncol 2024; 15(1): 23-31
URL https://www.wjgnet.com/2218-4333/full/v15/i1/23.htm
DOI https://dx.doi.org/10.5306/wjco.v15.i1.23
Full Article (PDF) WJCO-15-23-with-cover.pdf
Full Article (Word) WJCO-15-23.docx